<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122707">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919372</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-MTP-2012-74</org_study_id>
    <nct_id>NCT01919372</nct_id>
  </id_info>
  <brief_title>Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention</brief_title>
  <acronym>PREDIRCAM 2</acronym>
  <official_title>Intensificación y monitorización telemática Personalizada de la modificación Del Estilo de Vida en el Tratamiento de la Obesidad y la prevención Del Riesgo cardiometabólico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Netherlands: Ministry of Health, Welfare and Sports</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is based on the contribution that could offer a technological system  for  a
      continuous monitoring, individualized treatment of obesity and prevention of cardiometabolic
      complications  in high risk population.

      The main objective of PREDIRCAM study is to evaluate the benefits obtained with the use in
      high cardiometabolic risk individuals of a telemedical platform integrating applications for
      monitoring  and providing recommendations to improve lifestyle habits (diet and physical
      activity) in a healthier way.

      The study population are obese subjects (type I or II) aged between 25 and 65 years  with a
      12 month follow-up. In this population it will be analysed the cost-effectiveness of a
      telemedic assistance with a technological system and its ability to modify lifestyle habits,
      reduce weight and cardiovascular risk associated parameters.

      Previously to the clinical implementation, a pilot study for testing the telemedical system
      will be made. Efficacy and security variables will be evaluated along the study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiometabolic risk prevention</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Obesity Type I and II</condition>
  <arm_group>
    <arm_group_label>Conventional assistance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual treatment of obesity in terms of monitoring lifestyle habits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telemedic assistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Telemedic assistance with a technological system</intervention_name>
    <arm_group_label>Telemedic assistance</arm_group_label>
    <other_name>PREDIRCAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <arm_group_label>Conventional assistance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Preclinical Phase:

        1. People over 18 years with or without obesity and with ability for technology management

        Clinical Phase:

          1. People between 25 and 65 years.

          2. Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2:

               1. Grade I or II without sleep apnea syndrome and ischemic heart disease

               2. Absence of metabolic processes (dyslipidemia) or associated hypertension
                  requiring drug treatment at the time of inclusion in the study.

          3. People with ability for technology management

        Exclusion Criteria:

        Preclinical Phase:

        1. Serious illness and / or disabling

        Clinical Phase:

          1. Diabetes defining according to American Diabetes Association (ADA) criteria.

          2. Subjects with moderate to severe active disease at the time of inclusion in the study
             protocol

          3. Impaired glucose metabolism related diseases associated with diabetes mellitus or
             drugs interfering carbohydrate metabolism.

          4. Cardiovascular disease

          5. Dyslipidemia or hypertension requiring drug treatment.

          6. Alcohol consumption

          7. Pregnancy

          8. Serious illness and / or disabling
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cintia Gonzalez, MD PhD</last_name>
    <phone>+34610898918</phone>
    <email>cgonzalez@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cintia Gonzalez, MD PhD</last_name>
      <phone>+34610898918</phone>
      <email>cgonzalezb@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Cintia Gonzalez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
